News For OCR From The Last 14 Days Check below for free stories on OCR the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
January 30, 2012
|
| 16:16 EDT |  | OCR |
| | 12:14 EDT | | OCR |
| | 08:53 EDT |  | OCR |
| theflyonthewall.com: | Omnicare weakness a buying opportunity, says Barclays | | Barclays believes weakness in Omnicare (OCR) related to the FTC's decision to block its acquisition of Pharmerica (PMC) is a buying opportunity. The firm expects Omnicare to benefit from 2012 generics, organic growth, and some possibility a deal goes through. Shares are Equal Weight rated with a $37 price target. :theflyonthewall.com |
| | 08:32 EDT | | OCR |
| theflyonthewall.com: | Omnicare weakness would be a buying opportunity, says Cowen | | Cowen said they expected weakness in Omnicare (OCR) following the FTC's announcement it would block its merger deal with PharMerica (PMC). The firm said maintains its favorable view given improving fundamentals, including bed retention, increased automation, and specialty growth. Shares are Outperform rated. :theflyonthewall.com |
| | 06:39 EDT | | OCR |
| theflyonthewall.com: | Omnicare shares likely to pull back to $30-$31 range, says Leerink | | Leerink expects Omnicare (OCR) shares pull back to the $30-$31 range near-term after the FTC filed a complaint to block the company's proposed acquisition of PharMerica (PMC). However, the firm expects shares of Omnicare to move higher as disappointment about the deal passes and keeps an Outperform rating on the stock. :theflyonthewall.com |
| | 06:36 EDT |  | OCR |
| theflyonthewall.com: | FTC issues complaint to block Omnicare's acquisition of PharMerica | | The Federal Trade Commission announced last Friday that it issued a complaint to block Omnicare's (OCR) hostile acquisition of long-term care pharmacy provider PharMerica (PMC), alleging that the combination would harm competition and enable Omnicare to raise the price of drugs for Medicare Part D consumers and others. The FTC alleges that the combined company likely would be a "must have" for Medicare Part D prescription drug plans, which are responsible for providing subsidized prescription drug benefit coverage for most SNF residents and other Medicare beneficiaries. Omnicare responded by saying, "We strongly disagree with the FTC's decision to seek to block the proposed transaction." :theflyonthewall.com |
|
|
January 28, 2012
|
| 12:51 EDT | | OCR |
|
|
|
Subscribe for More Information